

Special Issue

Challenges in the Development of PET and SPECT Radiotracers: Innovative Ideas with Negative Outcomes

Message from the Guest Editors

We are pleased to announce a Special Issue dedicated to the challenges and innovative efforts in the development of PET and SPECT radiotracers. With this Special Issue, we will provide a space to present substantial research with negative results in the field of radiotracer development and seek to emphasize innovative ideas that, despite their potential, have resulted in supposedly unpublishable outcomes. We believe that knowing what fails is as important as knowing what succeeds to support a comprehensive understanding, encourage methodological improvements and finally strengthen the scientific community. It prevents duplications of efforts and contributes to a more reliable scientific literature. We therefore look forward to receiving your contributions in the fields of medicinal chemistry, radiochemistry, and in vitro and/or in vivo preclinical evaluation of newly developed radiopharmaceuticals. This Special Issue is open to original research articles, brief reports, and reviews.

Guest Editors

Dr. Magali Toussaint

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site, Leipzig, Germany

Dr. Barbara Wenzel

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site, Leipzig, Germany

Deadline for manuscript submissions

25 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/209260

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)